NorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate.
Author Archive for: TG
About Thomas Gabrielczyk
This author has yet to write their bio.Meanwhile lets just say that we are proud Thomas Gabrielczyk contributed a whooping 329 entries.
Entries by Thomas Gabrielczyk
4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Mercks checkpoint blocker avelumab plus 4SCs HDAC I blocker domatinostat.
Mutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund.
Critical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality.
Antabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients
Swedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds.
European Biotechnology Magazine will be back with breaking news and backgrounds on 2 January. Best wishes
The technology of Oxford-based Oxford Biodynamics (OBD) promises insights into why immunotherapies only work in some patients but not in all. A major US pharma company now wants to validate OBD’s epigenetic biomarker discovery and development platform causing a share price gain of 15%.
Paris-based European venture capital company Truffle Capital closed its 250m BioMedTech fund celebrating its company building approach.
Data from 1,200 heart failure patients demonstrate that high discharge levels of the biomarker bio-ADM® (bioactive Adrenomedullin) indicate residual congestion in heart failure patients.